KOSDAQBiotech & Pharma394800

3billion

₩6,230▲ 7.23%2026-11-18 close
Market Cap
₩198.3B
Turnover
₩3.1B
Volume
500K
Shares out.
31.8M
PER
135.3×
PBR
7.7×
EPS
₩47
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Growth and Narrower Losses; Sustained Profit Remains the Test

3billion more than doubled revenue in both 2024 and 2025 and cut its operating loss ratio sharply, but it has not yet reached operating profit, and quarterly net income swings with fair-value gains and losses on its convertible instruments.

  1. 1

    Annual revenue rose from KRW 2.73 billion in 2023 to KRW 11.7 billion in 2025, and the operating margin improved from -305.9% to -50.3% over the same period.

  2. 2

    Third-quarter 2026 revenue reached KRW 4.2 billion, up 30.0% from a year earlier, and has risen for two consecutive quarters since the first quarter of 2026. The operating loss narrowed to KRW 1.23 billion from the prior quarter.

  3. 3

    Net income attributable to controlling shareholders moved from a KRW 6.72 billion profit in the second quarter of 2026 to a KRW 2.73 billion loss in the third quarter. The company said first-half 2026 net income reflected non-cash fair-value gains on its convertible bonds (CB) and convertible preferred shares (CPS).

  4. 4

    Overseas sales were about 69% of first-half 2026 revenue, and rare-disease genetic testing made up 87.2% of cumulative revenue through the third quarter of 2026. The company is extending into newborn screening, family testing and AI-driven drug discovery.

  5. 5

    At the end of 2025, total equity was KRW 23.6 billion and total liabilities were KRW 6.07 billion, a debt ratio of 25.7%. Operating cash flow was negative in each year from 2023 to 2025, though the outflow narrowed every year.

02

Business structure

3billion is an AI-based rare-disease genetic testing company founded in 2016 that listed on KOSDAQ in 2024 as a technology growth company.

Its core business is rare-disease genetic testing built on whole exome sequencing (WES) and whole genome sequencing (WGS), and the company said this service accounted for KRW 9.9 billion, or 87.2%, of cumulative revenue of KRW 11.4 billion through the third quarter of 2026.

Service formats include full-service testing that covers everything from physician orders to interpretation, data-based diagnosis, a software subscription model (SaaS), and disease-specific tests. An iM Securities report from September 2025 noted that about 87% of 2024 revenue came from full-service testing.

Customers are concentrated among overseas healthcare providers: first-half 2026 overseas sales were about KRW 4.9 billion, or roughly 69% of the total, while domestic sales grew about 50% year on year.

In October 2026, on its tenth anniversary, the company said it had delivered results to more than 100,000 patients and that healthcare professionals in more than 75 countries use its tests.

The family-based test Family Insight, launched in February 2026, began generating mainly overseas sales, and the newborn screening test 3B-NEO, launched overseas in June 2026, was selected as a provider for a Philippine government newborn screening program.

The company is also pursuing AI drug discovery using patient genomic data accumulated through diagnostics, and on November 10, 2026 it signed a joint research agreement with France's Deeplife. In terms of competition, the US company GeneDx is cited as the peer group reference.

The same report estimated 3billion's cumulative data at more than 80,000 cases as of late July 2025, versus 150,000 to 180,000 for GeneDx.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.2B-₩1.3B−39.3%
2025Q4———
2026Q1₩3.4B-₩1.7B−49.4%
2026Q2₩3.8B-₩1.7B−43.9%
2026Q3₩4.2B-₩1.2B−29.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩2.7B-₩8.4B-₩5.1B−305.9%−43.2%93.9%
2024₩5.8B-₩7.4B-₩6.6B−128.5%−23.2%6.9%
2025₩11.7B-₩5.9B-₩5.4B−50.3%−22.9%25.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 2.73 billion in 2023 to KRW 5.77 billion in 2024, up 111.4% year on year, and then to KRW 11.7 billion in 2025, up 102.8%, roughly doubling again. Revenue grew for two consecutive years from 2024 through 2025, and 2025 was the largest year of the 2023 to 2025 period.

The operating loss was KRW 8.35 billion in 2023, KRW 7.42 billion in 2024 and KRW 5.89 billion in 2025, a loss for three consecutive years that narrowed each year. The operating loss as a share of revenue was -305.9% in 2023, -128.5% in 2024 and -50.3% in 2025.

Net loss attributable to controlling shareholders was KRW 5.09 billion in 2023, KRW 6.57 billion in 2024 and KRW 5.41 billion in 2025, so the net loss widened in 2024 even as the operating loss narrowed.

Because the two measures moved in opposite directions that year, non-operating items likely made the difference, although the figures alone do not pinpoint the cause. Net loss including non-controlling interests showed the same pattern, at KRW 5.41 billion in 2025.

Operating cash flow was -KRW 4.87 billion, -KRW 4.1 billion and -KRW 3.56 billion across 2023 to 2025, so the outflow narrowed every year but remained negative.

On a quarterly basis, revenue rose from KRW 3.23 billion in the third quarter of 2025 to KRW 3.36 billion in the first quarter of 2026, then to KRW 3.79 billion in the second quarter, up 12.8% from the prior quarter, and KRW 4.2 billion in the third quarter, up 10.7% from the prior quarter and 30.0% from a year earlier.

Quarterly operating losses were KRW 1.27 billion in the third quarter of 2025, KRW 1.66 billion in the first quarter of 2026, KRW 1.67 billion in the second quarter and KRW 1.23 billion in the third quarter, so the loss widened in the second quarter before narrowing in the third.

Net income attributable to controlling shareholders swung to a KRW 6.72 billion profit in the second quarter of 2026 and back to a KRW 2.73 billion loss in the third quarter.

The company said first-half 2026 consolidated net income of KRW 5.3 billion reflected non-cash fair-value gains on its CB and CPS, and that this was unrelated to an operating profit turnaround.

Net income attributable to controlling shareholders over the latest four quarters totaled KRW 1.52 billion, so quarterly results can change direction with fair-value items.

The company reported that its cumulative operating loss ratio for the first three quarters of 2026 fell from 61.8% to 40.2%, while cumulative ordinary R&D expenses rose about 36%.

05

Industry analysis

3billion operates in the rare-disease genetic testing market. A company profile summary describes the global rare-disease genetic testing market as being in a high-growth phase. An iM Securities report from September 2025 said roughly 10,000 rare diseases have known mechanisms, of which 80% are genetic disorders.

The same report noted that the company's tests generate revenue in about 70 countries. On the demand side, the company says demand for WES- and WGS-based diagnostics continues steadily.

In Korea, a supply contract tied to the Korea Disease Control and Prevention Agency's rare-disease diagnostic support program, signed with Pusan National University, was renewed and feeds into results. In competition, the US company GeneDx is cited as the main peer.

As of late July 2025, 3billion's cumulative data was estimated at more than 80,000 cases, against 150,000 to 180,000 or more for GeneDx. By the end of the third quarter of 2026, the company said its cumulative patient genome data had reached about 118,000 cases.

The same report, while noting the smaller data base, said repurchase rates from healthcare providers approach 80%, supported by model competitiveness and free reanalysis. The report also pointed out that revenue could grow quickly in test areas where insurance coverage applies.

On the cycle, first-half 2026 overseas sales rose 59%, confirming that overseas demand is driving growth. However, overseas sales reached about 69% of revenue, so changes in local regulation and reimbursement systems could have a large effect.

06

Outlook

The nearest variable for second-half 2026 results is how much revenue from new overseas tests gets recognized. The newborn screening test 3B-NEO launched overseas in June 2026 and was selected as a provider for a Philippine government newborn screening program.

In an August 2026 announcement, the company said related revenue would be reflected in stages starting in the second half. The family test Family Insight is also at the stage of generating overseas sales.

In the US, a company profile summary said the company set up a 100% subsidiary, 3billion US, Inc., and is preparing a local lab setup and CLIA certification. In October 2026, news reports said the company hired Vice President Eric Zmuda to speed up building and certifying its Austin lab.

An iM Securities report from September 2025 judged that the timing of meaningful US revenue depends on certification and securing medical insurance coverage. On drug discovery, research is continuing on 15 pipeline programs identified through the company's proprietary AI platform.

The joint research with Deeplife, signed on November 10, 2026, centers on validating therapeutic targets found in patient genomes with AI virtual cell technology and designing small-molecule candidates.

On funding, the company raised KRW 30 billion in 2026 through CB of KRW 12.5 billion and CPS of KRW 17.5 billion, and said the proceeds will go to expanding global diagnostics and AI drug discovery R&D. 2025 revenue exceeded the KRW 9 billion target the company presented at its IPO.

The next checkpoints are how much new overseas testing revenue shows up in the fourth-quarter 2026 preliminary results, and the trend in the operating loss ratio in the 2026 annual business report.

07

Valuation

PER
135.3×
PBR
7.7×
ROE
6.0%
EPS
₩47
BPS
₩829
Dividend per share
₩0

Earnings-based multiples look large because the company's net income attributable to controlling shareholders over the latest four quarters totals only KRW 1.52 billion.

Since quarterly net income swings between profit and loss with CB and CPS fair-value items, the range of interpretation for earnings-based multiples is also wide.

The price-to-book ratio reflects a substantial premium to net assets, with the share price well above the KRW 23.6 billion of total equity at the end of 2025. That premium can be read as reflecting expectations for the AI drug discovery pipeline and the overseas testing data asset while operating losses continue.

The dividend yield is effectively zero, so comparisons based on dividends do not carry much weight. Over multiple years the operating margin improved from -305.9% to -50.3%, a profit recovery that has not yet reached operating profit.

Because the convertible bonds and convertible preferred shares could increase the share count depending on conversion terms, the range of interpretation for per-share measures is also wide.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Sustained Revenue Growth

Revenue rose 111.4% in 2024 and 102.8% in 2025, and third-quarter 2026 revenue rose 30.0% from a year earlier. Revenue has increased for two consecutive quarters since the first quarter of 2026, and first-half 2026 revenue was up 56% year on year. Overseas sales, up 59% in the first half, have become the central driver of growth.

Rapid Improvement in the Operating Loss Ratio

The operating margin improved from -305.9% in 2023 to -50.3% in 2025. The cumulative operating loss ratio for the first three quarters of 2026 fell from 61.8% to 40.2%, even as ordinary R&D expenses rose about 36%. In the first half, revenue grew 56% while operating costs grew 29%, according to the company.

Data Assets and Expanding Business Scope

The company presents more than 120,000 patient genome datasets and 600,000 clinical case records as a shared foundation for diagnostics and drug discovery. In 2026 it raised KRW 30 billion through CB and CPS and signed a joint research agreement with Deeplife.

It has also been reported as selected for an AI innovation project under France's national investment program, France 2030.

09

Bear factors

Operating Losses Persist

The operating loss persisted for three consecutive years from 2023 through 2025, and a KRW 1.23 billion operating loss was recorded in the third quarter of 2026. Operating cash flow was negative in every year from 2023 through 2025.

The 2025 operating margin of -50.3% remains deeply negative, and no operating profit turnaround has yet been reported.

Dependence on Fair-Value Gains for Net Income

The company said first-half 2026 net income of KRW 5.3 billion included non-cash fair-value gains on its CB and CPS, unrelated to core operating profit. Net loss attributable to controlling shareholders returned to a KRW 2.73 billion loss in the third quarter of 2026.

Because quarterly net income moves sharply with fair-value items unrelated to operations, the underlying earnings trend is harder to read.

Overseas Dependence and Funding Burden

About 69% of first-half 2026 revenue came from overseas. High overseas dependence makes results more exposed to local regulation, insurance policy and exchange rates. The KRW 30 billion raised through CB and CPS strengthened funding, but conversion could increase the share count depending on terms.

10

Risk factors

Funding and Dilution

With operating losses continuing, the company raised KRW 30 billion through CB and CPS in 2026. Conversion of the convertible bonds and preferred shares would increase the number of shares outstanding.

Because the proceeds fund global diagnostics expansion and AI drug discovery R&D, funding needs could continue until the results of that spending become visible.

Regulation and Certification Timing

If the build-out of the US lab, CLIA certification and securing insurance coverage are delayed, the timing of visible US revenue could also slip. The September 2025 iM Securities report also identified this setup process as a precondition for revenue.

Domestic revenue depends in part on the renewal of public contracts such as the Korea Disease Control and Prevention Agency program.

Drug Discovery Uncertainty

The company is advancing research on 15 pipeline programs identified through its AI platform, but whether any candidate will reach clinical stages has not been disclosed. The Deeplife collaboration is still at an early stage focused on validating the biological rationale of therapeutic targets. If drug discovery results are delayed, R&D spending could continue to weigh on the operating loss.

11

What to watch next

  1. Around February 2027 (based on the timing of the 2025 annual preliminary results)

    Check how much 2026 fourth-quarter revenue reflects new overseas tests such as 3B-NEO, and whether the operating loss continues to narrow for a fourth consecutive year.

  2. By the end of March 2027 (annual business report filing deadline)

    Check whether the operating margin moved from -50.3% in 2025, and whether the operating cash outflow narrowed, in the 2026 annual business report.

  3. Mid-May 2027 (around the first-quarter report filing deadline)

    Look at the operating profit and loss trend excluding CB and CPS fair-value changes, and whether progress on the US subsidiary's CLIA certification shows up in quarterly results.

  4. Timing not set (to be confirmed through disclosures)

    Confirm whether the Austin lab obtains CLIA certification and begins US revenue, and what follow-on target validation results come from the Deeplife joint research.

12

Overall view

3billion grew revenue from KRW 2.73 billion in 2023 to KRW 11.7 billion in 2025, and third-quarter 2026 revenue rose 30.0% from a year earlier.

The operating loss has persisted for three consecutive years, but the operating margin improved from -305.9% to -50.3%, and the cumulative operating loss ratio for the first three quarters of 2026 fell to 40.2%.

On the other hand, quarterly net income attributable to controlling shareholders moved from a profit in the second quarter of 2026 to a KRW 2.73 billion loss in the third, and first-half net income reflected non-cash fair-value gains on CB and CPS. Operating cash flow was negative in every year from 2023 through 2025.

Overseas sales of about 69% make results more exposed to local regulation and certification timing. The drug discovery business is expanding with 15 pipeline programs and the Deeplife collaboration, but whether any candidate enters clinical stages has not been disclosed.

The next checkpoints are the fourth-quarter 2026 preliminary results and the operating margin in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.sedaily.com
  2. comp.wisereport.co.kr
  3. file.alphasquare.co.kr
  4. sedaily.com
  5. pharm.edaily.co.kr
  6. news1.kr
  7. news.nate.com
  8. m.news.nate.com
  9. news.nate.com
  10. edaily.co.kr
  11. newspim.com
  12. widedaily.com
  13. m.news.nate.com
  14. 3billion.io
  15. news.nate.com
  16. newspim.com
  17. fnnews.com
  18. rapportian.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis